Log in

NASDAQ:DCPHDeciphera Pharmaceuticals News Headlines

$46.90
+0.08 (+0.17 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$46.52
Now: $46.90▼
$48.37
50-Day Range
$46.07
MA: $52.15▼
$64.22
52-Week Range
$31.37
Now: $46.90▼
$71.11
Volume403,100 shs
Average Volume545,799 shs
Market Capitalization$2.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.98

Headlines

Deciphera Pharmaceuticals (NASDAQ DCPH) News Headlines

Source:
DateHeadline
Deciphera Pharmaceuticals (NASDAQ:DCPH) Downgraded by BidaskClubDeciphera Pharmaceuticals (NASDAQ:DCPH) Downgraded by BidaskClub
marketbeat.com - August 7 at 7:22 AM
Q3 2020 EPS Estimates for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Lifted by AnalystQ3 2020 EPS Estimates for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Lifted by Analyst
americanbankingnews.com - August 10 at 4:15 AM
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) to Post FY2023 Earnings of $2.88 Per Share, SVB Leerink ForecastsDeciphera Pharmaceuticals Inc (NASDAQ:DCPH) to Post FY2023 Earnings of $2.88 Per Share, SVB Leerink Forecasts
americanbankingnews.com - August 7 at 10:38 AM
Deciphera Pharmaceuticals Inc to Post Q3 2020 Earnings of ($1.26) Per Share, Jefferies Financial Group Forecasts (NASDAQ:DCPH)Deciphera Pharmaceuticals Inc to Post Q3 2020 Earnings of ($1.26) Per Share, Jefferies Financial Group Forecasts (NASDAQ:DCPH)
americanbankingnews.com - August 7 at 8:22 AM
Q3 2020 EPS Estimates for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Increased by AnalystQ3 2020 EPS Estimates for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Increased by Analyst
americanbankingnews.com - August 7 at 7:26 AM
Jefferies Financial Group Comments on Deciphera Pharmaceuticals Incs FY2024 Earnings (NASDAQ:DCPH)Jefferies Financial Group Comments on Deciphera Pharmaceuticals Inc's FY2024 Earnings (NASDAQ:DCPH)
americanbankingnews.com - August 6 at 8:32 AM
SVB Leerink Trims Deciphera Pharmaceuticals (NASDAQ:DCPH) Target Price to $54.00SVB Leerink Trims Deciphera Pharmaceuticals (NASDAQ:DCPH) Target Price to $54.00
americanbankingnews.com - August 5 at 11:53 AM
Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2020 Earnings Call TranscriptDeciphera Pharmaceuticals, Inc. (DCPH) Q2 2020 Earnings Call Transcript
finance.yahoo.com - August 5 at 8:21 AM
Deciphera Pharmaceuticals Inc (DCPH) CEO Steve Hoerter on Q2 2020 Results - Earnings Call TranscriptDeciphera Pharmaceuticals Inc (DCPH) CEO Steve Hoerter on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 5 at 1:09 AM
Deciphera Pharmaceuticals EPS beats by $0.17, beats on revenueDeciphera Pharmaceuticals EPS beats by $0.17, beats on revenue
seekingalpha.com - August 4 at 8:08 PM
Deciphera Pharmaceuticals (NASDAQ:DCPH) Trading 6.7% Higher Deciphera Pharmaceuticals (NASDAQ:DCPH) Trading 6.7% Higher
americanbankingnews.com - August 3 at 8:48 PM
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Receives Consensus Recommendation of "Buy" from BrokeragesDeciphera Pharmaceuticals Inc (NASDAQ:DCPH) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 2 at 5:17 PM
Deciphera Pharmaceuticals (DCPH) Scheduled to Post Earnings on TuesdayDeciphera Pharmaceuticals (DCPH) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - July 30 at 9:17 AM
Q3 2020 Earnings Forecast for Deciphera Pharmaceuticals Inc Issued By SVB Leerink (NASDAQ:DCPH)Q3 2020 Earnings Forecast for Deciphera Pharmaceuticals Inc Issued By SVB Leerink (NASDAQ:DCPH)
www.americanbankingnews.com - July 29 at 10:20 AM
FY2024 EPS Estimates for Deciphera Pharmaceuticals Inc Boosted by Analyst (NASDAQ:DCPH)FY2024 EPS Estimates for Deciphera Pharmaceuticals Inc Boosted by Analyst (NASDAQ:DCPH)
www.americanbankingnews.com - July 28 at 10:28 AM
$2.07 Million in Sales Expected for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) This Quarter$2.07 Million in Sales Expected for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) This Quarter
www.americanbankingnews.com - July 28 at 2:20 AM
Zacks: Brokerages Anticipate Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Will Announce Earnings of -$1.34 Per ShareZacks: Brokerages Anticipate Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Will Announce Earnings of -$1.34 Per Share
www.americanbankingnews.com - July 26 at 8:43 AM
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal TumorChina NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
finance.yahoo.com - July 20 at 7:44 AM
Decipheras Qinlock OKd in Australia for fourth-line gastrointestinal stromal tumorDeciphera's Qinlock OK'd in Australia for fourth-line gastrointestinal stromal tumor
seekingalpha.com - July 14 at 7:45 AM
Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal TumorDeciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
finance.yahoo.com - July 14 at 7:45 AM
Did Hedge Funds Make The Right Call On Deciphera Pharmaceuticals, Inc. (DCPH)Did Hedge Funds Make The Right Call On Deciphera Pharmaceuticals, Inc. (DCPH)
finance.yahoo.com - July 12 at 11:12 PM
Did Hedge Funds Make The Right Call On Deciphera Pharmaceuticals, Inc. (DCPH) ?Did Hedge Funds Make The Right Call On Deciphera Pharmaceuticals, Inc. (DCPH) ?
finance.yahoo.com - July 12 at 11:12 PM
Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GISTDeciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST
finance.yahoo.com - July 2 at 4:40 PM
Decipheras ripretinib OKd in Canada for 4th-line GISTDeciphera's ripretinib OK'd in Canada for 4th-line GIST
seekingalpha.com - June 22 at 10:04 AM
Deciphera Announces Health Canadas Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal TumorDeciphera Announces Health Canada's Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
www.benzinga.com - June 22 at 10:04 AM
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology ForumDeciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum
finance.yahoo.com - June 11 at 8:00 AM
Deciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet OncologyDeciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology
finance.yahoo.com - June 8 at 7:44 AM
Hedge Funds Have Never Been More Bullish On Deciphera Pharmaceuticals, Inc. (DCPH)Hedge Funds Have Never Been More Bullish On Deciphera Pharmaceuticals, Inc. (DCPH)
finance.yahoo.com - June 6 at 12:59 PM
Deciphera Prepares To Collect Revenue After First FDA Approval: We Are Well-PositionedDeciphera Prepares To Collect Revenue After First FDA Approval: 'We Are Well-Positioned'
www.benzinga.com - May 29 at 3:03 PM
Deciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCKTM (ripretinib) in Patients with Fourth-Line Advanced GIST at the ASCO 2020 Virtual Scientific ProgramDeciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCKTM (ripretinib) in Patients with Fourth-Line Advanced GIST at the ASCO 2020 Virtual Scientific Program
finance.yahoo.com - May 29 at 10:03 AM
Deciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer at the ASCO 2020 Virtual Scientific ProgramDeciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer at the ASCO 2020 Virtual Scientific Program
finance.yahoo.com - May 29 at 10:03 AM
News Flash: Analysts Just Made A Captivating Upgrade To Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) ForecastsNews Flash: Analysts Just Made A Captivating Upgrade To Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Forecasts
finance.yahoo.com - May 26 at 8:25 AM
FDA Approval Could Be a Game-Changer for Deciphera PharmaceuticalsFDA Approval Could Be a Game-Changer for Deciphera Pharmaceuticals
finance.yahoo.com - May 23 at 9:01 AM
Decipheras GIST Approval, And Other News: The Good, Bad And Ugly Of BiopharmaDeciphera's GIST Approval, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - May 19 at 5:42 AM
Nomura Sticks to Their Hold Rating for Deciphera PharmaceuticalsNomura Sticks to Their Hold Rating for Deciphera Pharmaceuticals
finance.yahoo.com - May 18 at 1:12 PM
Deciphera Pharmaceuticals Just Surged Higher On A New Rapid ApprovalDeciphera Pharmaceuticals Just Surged Higher On A New Rapid Approval
finance.yahoo.com - May 18 at 1:12 PM
Deciphera (DCPH) Secures Early FDA Nod for GIST Drug QinlockDeciphera (DCPH) Secures Early FDA Nod for GIST Drug Qinlock
finance.yahoo.com - May 18 at 1:12 PM
Deciphera shares halted pending newsDeciphera shares halted pending news
seekingalpha.com - May 16 at 8:10 AM
FDA OKs Decipheras ripretinib for GISTFDA OKs Deciphera's ripretinib for GIST
seekingalpha.com - May 15 at 8:03 PM
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Analysts Just Trimmed Their Revenue Forecasts By 14%Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Analysts Just Trimmed Their Revenue Forecasts By 14%
finance.yahoo.com - May 12 at 8:27 AM
Earnings Update: Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Just Reported And Analysts Are Trimming Their ForecastsEarnings Update: Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Just Reported And Analysts Are Trimming Their Forecasts
finance.yahoo.com - May 8 at 5:36 PM
Deciphera Pharmaceuticals EPS misses by $0.05, misses on revenueDeciphera Pharmaceuticals EPS misses by $0.05, misses on revenue
seekingalpha.com - May 5 at 8:37 PM
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2020 Financial ResultsDeciphera Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results
finance.yahoo.com - May 5 at 8:37 PM
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue EstimatesDeciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 5 at 8:37 PM
Blueprint Medicines Tumbles 20.8% on Phase 3 Study FailureBlueprint Medicines Tumbles 20.8% on Phase 3 Study Failure
finance.yahoo.com - April 28 at 1:06 PM
Blueprints avapritinib pain is Decipheras gain, up 16%Blueprint's avapritinib pain is Deciphera's gain, up 16%
seekingalpha.com - April 28 at 8:06 AM
Deciphera Pharmaceuticals, Inc. to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5, 2020Deciphera Pharmaceuticals, Inc. to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5, 2020
finance.yahoo.com - April 28 at 8:06 AM
Is Deciphera Pharmaceuticals (DCPH) Stock a Solid Choice Right Now?Is Deciphera Pharmaceuticals (DCPH) Stock a Solid Choice Right Now?
finance.yahoo.com - April 23 at 12:43 PM
Is Deciphera Pharmaceuticals a Buy?Is Deciphera Pharmaceuticals a Buy?
www.fool.com - April 22 at 8:00 AM
Deciphera Pharmaceuticals, Inc. (DCPH) - Insider TransactionsDeciphera Pharmaceuticals, Inc. (DCPH) - Insider Transactions
www.fool.com - March 28 at 12:02 AM
Deciphera Pharmaceuticals IncDeciphera Pharmaceuticals Inc
www.bloomberg.com - March 24 at 9:27 PM
This page was last updated on 8/14/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.